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Patients and Methods: Children aged 0-1 5 years with serolog- 
icdy confirmed TBE, hospitalized from January 1982 to October 
1996 were included in the study. Sequelae were assessed at the &s- 
charge from the hospital, at six months and later $indicated. 
Results: During 15 years 256 children with TBE were hospital- 
ized. No deaths were recorded. In 24 (10%) children sequelae were 
present at the discharge &om the hospital. At follow-up, 6 patients 
W y  recovered, 5 showed mild, 9 moderate and 4 severe sequelae. 
TBE specific immunoglobulin was not used in patients who devel- 
oped sequelae. Boys were afXected more frequently. The severity of 
sequelae was strongly age related, and severe sequelae were observed 
only in patients over 5 years of age. It seems that the severity of the 
&ease increased in the last years. 
Conclusion: Contrary to common belief, severe forms of TBE 
with long lasting or permanent sequelae occur in childhood. Rou- 
tine immunizadon in endemic areas is therefore strongly advocated. 
gen of these viruses as well as viruses Inko, Showshoe hare, Sindbis, 
Crimean hemorrhagic fever, hemorrhagic fever with kidney syndrome were 
found in 166 cases. In Volyn, Lviv, Transcarpathian regions and in 
the Crimea active focuses with group occurrence of diseases among 
the people and high infection of ticks (6.3-19.5%), s m a l l  fnamrnaE 
(8.3-15.9%) and presence of seropositive to tick-borne encephalitis 
people. Active focuses of WN virus whch manifested themselves in 
group occurrence of diseases in people in Tianscarpathian, Cherkasy 
and Kherson regions. Infection of mosquites in this focuses was 
10.0-12.5%. and the number of seropositive to WN viruses people 
was 21.4-36.3%, Of the patients with acute season neuroinfections 
in 23.5% arboviral etiology was established by laboratory investiga- 
tions. 
Conclusions: The performed investigations teshfy to intensive 
circulation of arboviruses in Ukraine and their essential role in in- 
fectious pathology. 
I PI 394 1 Clinical Aspects of TBE in Lithuania 
A. Lais'konis I ,  V. Mationiene ', D. Velyvyte I .  'Kaum Medical 
Academy, Kaunas, Lithuania, 'Kaunac Clinical Hospital ofInfectious 
Diseases, K a u m ,  Lithuania 
Objective: To analyse and to present the epidemiological and clini- 
cal characteristics of tick-borne encephalitis (TBE) in Kaunas region 
in Lithuania. 
Methods: There are presented all cases of adult patients that were 
treated for TBE in Kaunas Clinical Hospital of Infectious Diseases 
in the period of 17 years (1979-1995). Epidemiological and clinical 
characteristics and laboratory diagnosis confirmation were analyzed. 
The dagnoses of TBE cases were based on epidemiologic history, 
clinical picture, and detection of antibodies in the paired sera, using 
the hemagglutination irhbition test. 
Results: In the period of 1979-1995 there were diagnosed 326 
cases of TBE. 71.78% of the patients were able to recall the fact 
of tick bite that took place 1-4 weeks before the onset of the dis- 
ease. Only 27.3% of the patients were sent in with suspicion of 
TBE. There were 55.55% of males and 44.45% of females, preva~I- 
ing age - 2 M O  years. Among the clinical manifestation of disease 
the headache (98.8%), nausea (77.7%), vomiting (54.68%), muscle 
aches (33.23%) and increased temperature (100%) were the most 
fkquent. Only 29.62% of the patients came to the hospital up to 
the 5th day of manifestation. The majority of patients was adrmtted 
to the hospital in August, September and October (76.05%). It is 
important to point out the presence of meningoencephaktic (66%) 
and meningitic (20%) forms. The results of spinal fluid analysis re- 
vealed the view of seromeningitis. In hemagglutination - inhibition 
reaction there was a growth in antibodies titre in 90% of cases. 
Conclusions: In Lithuania TBE is an actual problem that may be 
solved by vaccination of risk groups and individual persons. 
1 PI 395 I Study of Arboviral infections in Ukraine 
I .  Vynograd, G. Biletska, I .  Lozynsky, M. Kozlovsky, V. Plastunov. 
SRI of Epidemiolon, Lviq Ukraine 
Objectives: Ecology of arboviruses, etiology and natural centrality 
of arboviral infections. 
Methods: Strains of arboviruses were isolated on newborn white 
mice and in culture. Antigens of arboviruses and antibodies were 
found in ELISA and complement binding response. 
Results: 123 sna ins  of arboviruses of tick-borne encephalitis, Waf 
Nile (whr), Ehtai, Tahyna, Tribec, Ukuniemi were isolated h m  ticks, 
mosquites, small mammals, birds, patients with neuromfections on 
newborn white mice. In observation of these objects in ELISA anti- 
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-1 Cost-Effectiveness of Different Vaccination 
E! Zurn I ,  R. Kammerlander *, J.-F! Danthme I .  'Department of 
Econometrics and Economics, Uniuersity oflausanne, Switzerland, 'Swiss 
Federal O&e ofPublic Health, Bern, Switzerland 
Objectives: To assess and compare the costs and epidemiologi- 
cal impact of different vaccination strategies against hepatitis B in 
Switzerland. 
Methods: A birth cohort 85,000 individuals was followed over 
its Metime using a decision tree analysis. Pubhhed data were used 
to simulate the risk of hepatitis B virus (HBV) infection in the co- 
hort, the consecutive clinical outcomes and the associated costs. Five 
vaccination scenarios were assessed and compared to the baseline, de- 
fined as the current high-risk group strategy without prenatal screen- 
ing. These were: 1. systematic prenatal screening and vaccination of 
newborns at r i s k ;  2. universal vaccination of dants; 3. universal 
vaccination of schoolchddren; 4. universal vaccination of mfants and 
schoolchildren; 5. universal vaccination of infants, schoolchildren 
and adolescents. Results are presented using a 3% annual discounting 
rate. 
Results: Systematic prenatal screening reduced the number of 
chronic infections by 11% and prevented 6 deaths per year. The 
cost per year of life saved was estimated to be 23,350 CHE The 
four universal vaccination scenarios had a much larger impact on 
the number of chronic infections and deaths prevented (reduction 
of 68-78%). Costs per year of life saved for universal vaccination 
ranged h m  8820 CHF (mfant strategy) to 12,380 CHF (schoolchil- 
dren strategy). However, the vaccination of schoolchildren would 
be as cost-effective as the vaccination of infants using alternative 
assumptions. 1. a lower compliance rate for d i n t s  compared to 
schoolchddren; 2. the need for a booster for dints. 
Conclusion: Universal vaccination against hepatitis B is more 
cost-effective than the current selective vaccination strategy and 
would substantially reduce the number of chronic infections and 
deaths caused by HBV infections in Switzerland. 
Strategies against Hepatitis B in Switzerland 
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ml Clinical Trial of Simultaneous Administration of 
Recombinant Hepatitis B Vaccine and Tetanus 
Toxoid in Nonresponders 
E. Sonmez I ,  I.H. Ozerol I ,  Y. Char I ,  K. Sahin I ,  H. Ozbilge ', 
G. Arslan ', S .  Ytlmaz 3,  K. Kilicturgay 4 .  ' iniinii University School .f 
Medicine, Malatya, Turkey, 'Harran University School $Medicine, U& 
Turkey, 'Ataturk University School of Medicine, Erzurum, Turkey, 
4Uludag University School ofMedicine, Bursa, Turkey 
Objectives: To compare the antibody responses to Pre S2 + S con- 
taining recombinant hepatitis B vaccine (S2SRHB) and S2SRHB + 
Tetanus toxoid (TT) in the nonresponders. 
Methods: We assessed the efficacy of tetanus toxoid (TT) and Pre 
S2 + S containing recombinant hepatitis B vaccine (S2S RHB) in' 
10 nonresponders to S2SRHB. We applied simultaneous administra- 
tion of S2SRHB and TT to ten persons (group I) who did not to 
respond (anti-HBs t10 IU/mL) after 3 doses of S2SRHB (gwen as 
20 ygr/one dose, intramuscularly (i.m), in months: 0-1-2). 6 non- 
responders (group 11) received 3 additional doses by the same route 
as the initial vaccination (SZSRHB, i.m, 1 mo. Interval). 
Results: In group I, after first S2SRHB +TT dose 2/10 (20%) 
responded with anti-HBs levels >10 IU/mL and after the second, 
another 3/10 (30%) responded and after the third, no more 0/10 
(0%) responded, corresponding to a total response rate of 50%. 
In group 11, after the first additional S2SRHB dose, 0/6 (0%) re- 
sponded, with anti-HBS levels t10 IU/mL, after the second, 1/6 
(16.66%) responded with anti-HBs level 15 IU/mL and after third 
dose no additional nonresponse was noted. Both seroconversion rate 
and the antibody titer level for anti-HBs antibody were sigdcantly 
higher in group I than in group I1 (p t 0.05). 
Conclusion: These results suggest that simultaneous administra- 
tion of S2SRHB and TT is more effective in nonresponders than 
additional doses given by the same route as the initial vaccination. 
lp1398I Comparative Immune Response of Two 
Commercial Hepatitis B Vaccines 
E. Sonmez I ,  I.H. Ozerol I ,  Y. Char I ,  K. Sahm I ,  H. Ozbllge ', 
G. Arslan' , .  S Ydmaz3. 'ittonu University School $Medicine, Malatya, 
Turkey, 'Harran University School $Medicine, U@, Turkey, 'Atatiirk 
University School of Medicine, Erzurum, Turkey 
Objectives: To describe results of a randomized, blinded trial com- 
paring the immunogenicity and tolerability of an investigational; 
yeast recombinant Hepatitis B Virus (HBV) vaccine containing S 
antigen with a recornbinant HBV vaccine containing pre S2 + S 
( h m  Chinese hamster ovary cell: CHO). 
Methods: One hundred healthy, HBV seronegative persons were 
enrolled in a single blind randomized study to compare antibody and 
clinical responses to yeast recombinant S antigen vaccine (YSHBV) 
(Hepavax-gene, 1 mL: 20 pgr/one dose) and CHO recombinant 
Pre S2 + S vaccine (CS2SHBV) (Genhevac B, 0.5 mL: 20 ygr/one 
dose). 50 participiant (group I) received 20 ygr ofYSHBV by intra- 
muscular (im) injection at 0 , l  and 6 months. 50 partcipiants (group 
11) received 20 ygr of CS2SHBV by i.m injection at 0, 1 and 2 mo. 
serological and biochemical responses were measured at 0, 1, 2, 3, 6 
and 7 months in both groups. 
Results: The proportion of vaccines with minor local complaints 
(mainly local pain, myalgia) and proportion developing antibody to 
surface antigen (Anti-HBs) were s d a r  for both vaccine groups (p 
> 0.05). But Anti-HBs titers were generally higher among recipients 
of CS2SHBV Anti-HBs developed in 92% and 96%, in group I and 
11, at 7 month, respectively. 
Conclusions: These data imply that YSHBV vaccine is as well 
tolerated and immunogenic as CS2SHBV vaccine. However, further 
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studies should be necessary to compare duration of immunity at a 
long time points after vaccination for two vaccines. 
I PI3991 Persistence of Anti-HBc Antibodies at Children 
Vaccinated against Hepatitis B 
L. Roinovskjr I ,  I. Lochman ', L. Lukitov6 I ,  A. Sulikovl 
'Department of Infectious Diseases, Teaching Hospital, Ostraua, Czech 
Republic, 2Deparfment of Immunology and Allergology, Regional Institute 
ofHygiene, Ostraua, Czech Republic 
Objectives: The long-term persistence of anti-HBc and the risk of 
hepatitis B infection at children vaccinated against hepatitis B were 
investigated. 
Methods: The passive-active immunisation of 374 newborns 
against hepatitis B was started in the year 1988. AU mothers were 
HBsAg positive at pregnancy, 19 of them were both HBsAg and 
HBeAg positive. The children received 50 IU of HBIG at birth 
and three 10-yg doses of plasma-derived or recombinant vaccine 
(H-B-vax, Engerix B) at 0, 1 and 6 months. The basic vaccination 
was finished at 331 children, 127 of them were revaccinated. Blood 
samples were tested by ELISA for anti-HBc (Sorin Biomedica, Italy) 
and for HBsAg, anti-HBs (Sevac, Czech Republic; Sorin Biomedica, 
Results: Antibodies anti-HBc were checked at 347 children. 
Anti-HBc was found in 10 h x n  226 sera in the second year of 
their life, in 9 f b m  123 sera in the third, in 2 h m  66 sera in the 
forth year and in 1 h m  126 sera at older children. Only one boy 
was HBsAg positive and suEered hepatitis B. The new appearance of 
anti-HBc with increase of anti-HBs was observed at 1 child. New 
appearance of anti-HBc antibodies without increase of anti-HBs was 
described at 12 children, but 9 of them had only short persistence 
of anti-HBc. The increase of anti-HBs without revaccination was 
observed at 19 children. 
Conclusion: Anti-HBc antibodies were found in 7.3% sera in the 
third year of life and 1.6% sera of elder children vaccinated against 
hepatitis B. In our study hepatitis B was described only at one child. 
Grant support: Ministry of Health, Czech Republic (IGA 
3520-3). 
Italy). 
I PI400 I Possibilities of Mass Vaccination against viral 
R. Prymula, J. Beran, M. Spliao. Purkyne Military Medical Academy, 
Hradec Krhlovt!, Czech Republic 
The universal vaccination against VHB is the only really effective 
way to fight the infection of hepatitis B v i n ~ s  as the methods of 
vaccination of risk groups cannot fully elirmnate the disease. 
The objective of OUT study was to judge the feasibility of intro- 
ducing this measure in our local situation, especially in view of the 
current epidemiological situation and economical aspects. 
Methods: We have tried to calculate the direct and indirect eco- 
nomical costs related to VHB in the Czech Republic in 1995. The 
total sum 100 mi0 Kc (4 mi0 USD) was compared in the van 
Damme model with a) vaccination cost of new-born mass vac- 
cination by a DTP-HB tetravaccine, b) adolescent vaccination, c) 
vaccination of both these groups. 
Results: In spite of descending trends and current incidence 
rate 6-7/100 000, prevalence of HBsAg varies between 0.5-0.67%. 
Based on the treatment data a quaLfied estimate was made of the di- 
rect costs over 30 mi0 Kc (1.2 mi0 USD) in 1 year and the indirect 
costs over 70 mi0 Kc (2.8 mi0 USD). 
Conclusions: It is necessary to judge all the facts and in spite of 
high initial costs, to introduce the mass vaccination as recommended 
Hepatitis B in the Czech Republic 
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by WHO. The experience &om other countries (Italy, Germany, 
Poland, Spain, US) shows that this is the correct approach. 
1P1401 1 The Association between Measles Vaccine 
Response and HLA-DQA1 Alleles 
M. Hayney, G. Poland, D. Rabe, D. Schaid, R. Jacobson, 
S .  Jacobsen, J. Lipsky, €? Wollan. Mayo Vaccine Research Group, 
Minnesota, USA 
Background The range of antibody (Ab) responses to measles vac- 
cine (MV) virus may be explained by genetic Ckversity among the 
genes of the HLA cluster. As part of a large study, we sought to 
determine the role of HLA-DQA1 genes in predicting MV Ab re- 
sponse. 
Methods: We determined the seroprevalence of measles Ab in 
880 school children immunized with MMR-I1 at age 15 months. 
Ab levels were determined by a whole virus EIA Subjects who 
were non-responders (NFb) [n = 461 (IgG seronegative) and hy- 
per-responders (HRs) [n = 681 (upper 10th percentile of IgG levels) 
were DQAl typed using PCR-SSP DQAl allele frequencies and 
homozygosity rates were compared between the two groups. 
Results: The allele kequency distribution between the NRs and 
HRs was sipficantly Ckfferent (p = 0.05) with NRs having more 
DQA1*05 alleles (p = 0.017) and HRs having more DQAI'OI alle- 
les (p = 0.016). The homozygosity rate among NRs was significantly 
higher than among HRs (21.7% vs. 8.8%, p = 0.037). 
Conclusions: These data suggest an association between 
MV-induced Ab response and the distribution of DQAl alleles. The 
presence of DQA1*05 alleles is associated with nonresponse and 
DQA1'01 alleles with hyper-response. In addition, DQAl homozy- 
gosity is a significant a predictor of poor Ab response to measles 
vaccine. 
]p14021 Measles Revaccination Among Bolivian 
A. Bartoloni', ET. Cum', P. Gughelmem3, D. Brown4, 
M.L. Bianchi Bandinelli3, H. Hurtado ', M. Roselli'. 'University .f 
Florence, Italy, 'London School $Hygiene and Tropical Medicine, L'K, 
University of Siena, Italy, 4Central Public Health bboratory, London, 
UK, 'Senetaria Regional de Salud, Santa Cruz, Bolivia, Italy 
Objectives: To evaluate the response to revaccination among Boli- 
vian cMdren with low or absent measles antibody levels by haemag- 
glutination ihbit ion (HI). 
Methods: We revaccinated 202 chddren, aged 5-16 years, whose 
antibody levels were below 200 mlU by HI in a serosurvey con- 
ducted in April 1993 in Santa Cruz, Bolivia. A blood sample was 
collected immediately before vaccination (TO), 4 weeks later (Tl), 
and 1 year after revaccination (T2) only h m  seroconverters. Sera 
were assayed by HI and by plaque reduction neutraluation assay 
(PRN). Sera collected 4 weeks post-vaccination were assayed for 
measles-specific IgM by enzyme-linked immunosorbent assay (EIA). 
Results: Ofthe 202 revaccinated children, 148 (73%) showed high 
measles IgG levels at TO. A measles outbreak occurred in Santa Cruz 
about 6 months earlier. Of these 148, only 9 (6%) gave a history of 
measles since the 1993 survey. Ofthe 54 children with HI times t500 
at TO, 20 (37%) had no detectable HI antibody, and 34 (63%) had low 
antibody levels. Among 20 pre-revaccination seronegatives, 19 (95%) 
were seropositive at T1. None had a positive IgM response. Among 28 
evaluable children with low HI antibody at TO, 12 (43%) had a four- 
fold increase at T1. At T 2 , l l  of 16 (69%) evaluable pre-revaccination 
seronegative had a fourfold decrease in titre, and 3 had antibody lev- 
els t200  mlU. Among 12 pre-revaccination seropositives, 4 (33%) 
Children With Low or Absent Antibody Titre 
had a fourfold decrease, 6 a two-fold decrease, and 7 had levels <200 
mlU. Among pre-revaccination seronegatives, the geometric mean 
titre (GMT) at T1 was 3933 by HI and 2062 by PRN. At T2, GMTs 
were 500 and 1093 by HI and PRN, respectively. 
Discussion: No primary vaccine failures were detected. Chil- 
dren who responded to revaccination with a fourfold or greater rise 
in antibody titre should be considered as susceptible to reinfection. 
However, data h m  the recent outbreak suggest that the risk of 
developing symptomatic measles in these children is low. The persis- 
tence of antibody after revaccination was short. 
1 PI403 I Postvaccination Immunity Against Measles in 
Children, Residing on 
Radionuclide-Contaminated Territories of 
Belarus 
E. Samoilovich, L. Kapustik, E. Feldman. Byelorussian Research 
Institutefor Epidemiology and Minobioloa, Minsk, Republic of Belams 
Objectives: To study the specific immunity against measles as well 
as to test the content of serum immunoglobulins classes G, A, and M 
in chddren, permanently exposed to low doses of ionizing radiation. 
Methods: We examined 103 pre-school children &om radionu- 
clide-contaminated territories, immunized wth  a single dose of live 
measles vaccine, and 98 children h m  "non-contaminated" areas 
(controls) of the Republic. Specific measles antibodies were deter- 
mined by means of passive hemagglutination assay, specific lympho- 
cyte proliferative activity was measured in the reaction of lympho- 
cyte blasttransformation with antigens of measles vaccine, and serum 
immunoglobulin concentrations were analyzed by radial immunod- 
iffusion technique. 
Results: Reliably lower lymphocyte proliferative activity to anti- 
gens of measles vaccine was registered among children, residing 
on radionuclide-contaminated territories. Besides, we identified the 
decrease of antibody-mediated measles immunity: the percent of 
seropo-sitive children constituted 68.4% versus 98.0% in controls 
(p <: 0.05), and geometric mean titers of hemagglutinin-antibodies 
made up 1.80 Ig versus 1.35 Ig (p < 0.05). Changes in specific 
postvaccination immunity were observed on the background of dis- 
balance in serum immunoglobulin production: IgG concentration 
was lower than in controls (6.37 f 0.38 g/l and 8.26 f 0.40 gfl, 
respectively, p < 0.05), but IgM concentration was higher (1.23 f 
0.16 g/l and 0.77 f 0.04 g/l, respectively, p cz 0.01). 
Conclusions: The detected deviations in the children's immu- 
nity allow one to consider the radionuclide-contaminated territories 
as risk areas of disturbances in immunity response, including post- 
vaccination immunity. 
I PI404 I Immunity to Measles-, Mumps-, Rubella-, and 
Polioviruses in Medical Students at the 
University of Bern, 1996 
R. Schaub, L. Matter, D. Germann. Institute ofMedical Microbiola, 
University .f Bern, Switzerland 
Objectives: To identlfy medical students lacking antibodies to 
measles-, mumps-, rubella- and polioviruses, and to offer them vac- 
cination. 
Methods: IgG antibodies to measles-, mumps-, and rubellaviruses 
in the sera of 141 students sera were determined by commercially 
available ELISA assays. Sera h m  130 students were tested for neu- 
tralizing antibodies to polioviruses types 1-3 using a modified mi- 
croplate neutralization assay. Students lacking antibodies to at least 
one of those viruses were contacted and offered to receive the re- 
spective vaccine. 
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Results: Four male students lacked antibodies to rubellavirus. 
Evidence of immunity to measles- and mumpsvirus was absent in 9 
(Em = 45) and 18 (Em = 8:lO) subjects, respectively, and one male 
student had no IgG to both measles- and mumpsvirus. 31 of those 
32 students were eventually vaccinated with the Mh4R vaccine. 
Only one female student lacked neutralivng antibodies to po- 
lioviruses l, 2 and 3. She had never received polio vaccination and a 
primary course of this vaccine was recommended. 
Conclusion: The determination of antibodes to measles-, 
mumps-, and rubellaviruses in medical students in order to vacci- 
nate subjects lacking immunity seems justified with respect to the 
potential risk of being exposed to patients and of being the source 
of a preventable infection for their future patients. 
I PI4051 Measles Immunity After Vaccination: Results in 
D. Colak', G. Din$', D. O@n$', M. Aktekin'. 'Akdeniz 
University Medical Faculty Clinical Microbiology Department, Antalya, 
Turkey, 2Public Health Department, Antalya, Erkey 
Objectives: We analyzed serum samples of children between the 
ages 4-6 years who had been vaccinated before 12 months of age to 
evaluate measles seropositivity. 
Methods: Sera collected from 140 children between the ages 4-6 
years who were selected by random sampling procedure in a squatter 
area, Antalya, Turkey. The children had been vaccinated before 12 
months of age and had not received booster dose. Anti-measles IgG 
antibodies were assayed by ELISA method. 
Results: Anti-measles IgG w a s  detected in 122 of 140 (87%) 
serum samples of children. 
Conclusion: We found a high rate of measles seropositivity in 
children between the ages 4 4  years who had been vaccinated before 
12 months of age and who had not received booster dose. Further 
studies are needed to define the timing of booster dose for children 
of this region. 
Children Vaccinated Before 12 Months of Age 
I PI406 I Safety and lmmunogenicity of a New 
DTPa-HBV-HIB Combination Vaccine for 
Primary lmmunisation of Infants 
€? Habermehl ' , M. Knuf' , W. Mannhardt ' , A. Schuind 
C.  Rebsch ' , €? Schmidtke ', M. Slaoui ', R. Clemens ', E Zepp 
' Childrenc hospital, Univeaity Mainz, Germany, SmithKZine Beecham 
Bio., Rixencart, Belgium 
Objectives: To compare the safety and immune response in in- 
fants vaccinated with 3 doses of PRP-tetanus conjugate mixed with 
a combined DTPa-HBV vaccine to a control group that received 
separate injections of DTPa-HBV and PRP-tetanus conjugate in 
opposite h b s .  
Methods: 487 infants were vaccinated at 3, 4 and 5 months of 
age and a booster consisting of unconjugated PRP was administered 
separately or mixed with DTPa-HBV in the second year of life. 
Antibody concentrations were measured before and after primary 
vaccination and booster dose. 
Results The primary course of tetanus-PRP elicited a good hu- 
moral immune response, 95.5% of all subjects having seroprotective 
anti-PRP concentrations 20.15 pg/ml. by the time of the booster, 
this proportion had declined to 81.2% in the groups given separate 
DTPa-HBV and Hib vaccines and to 47.8% in the groups given mixed 
DTPa-HBV/Hib vaccines. However, the booster elicited a marked 
and rapid increase in anti-PRP-antibodies in all groups. Antibody 
concentrations > 1 .O pg/ml, a value associated with long-term pro- 
tection, occurred in 86.4-97.9% of the vaccinees. The DTPa-HBV 
components elicited protective antidiphtheria, anti-tetanus (>0.1 
IU/ml) and anti-HBs antibody levels (>lo mIU/ml) in r98.5% of 
the infants. Mixture of these antigens with Hib in one syringe did not 
influence immune response to these antigens. 
Conclusions: Although there seems to be interference of the 
Hib-vaccine after primary vaccination (low titres), the antibody re- 
sponse to the booster indicates effective priming with the combina- 
tion vaccine. 
m1 Evidence for Polysaccharide-Specific 
B-Cell-Memory in the First Year of Life: Plain 
Hib-PRP as a Booster after Priming with a 
TT-Conjugate Hib-Vaccine 
M. Knuf', €? Habermehl', W. Mannhardt', A. Schuind', 
A. Kaufhold ', M. Slaoui ', R.  Clemens *, H.-J. Schmitt ', 
E Zepp ' . ' Childrens Hospital, University Mainz, Germany, 
'SmithKline Beecham Bio., f iemart ,  Belgium, Childrens Hospital, 
University Kiel, Germany 
Objectives: To investigate whether conjugated-PRP-vaccines in- 
duce polysaccharide-specific B-cell-memory in the first year of life. 
Methods: We examined the immune response to a dose of uncon- 
jugated Polyribosyl-ribitol-phosphate PRP) admmstered in the sec- 
ond year of life to children primed with three doses of PRP-tetanus 
conjugate reconstituted with a diphtheria-tetanus-acellular pertus- 
sis-hepatitis B vaccine (DTPa-HBV) at 3 ,4  and 5 months of age. A 
measurable immune response to a booster dose of plain PRP should 
provide evidence for the existence of immunological memory from 
a primary vaccination course. 
Results: The unconjugated PRP elicited protective anti-PRP an- 
tibody levels (>0.15 pg/ml) in all but 3 of the 369 vaccinees, in- 
cluding 13 infants who failed to demonstrate a measurable immune 
response after primary course. In a sub-cohort of 54 subjects dl 
had anti-PRP levels 20.5 wg/ml within 7-14 days of the booster 
showing a rapid anamnestic type response. Both primary and booster 
responses were predominantly IgG 1 indicating a T-cell dependent 
response. 
Conclusions: For the first time we prove the induction 
of polysaccharide specific B-cell-memory by a PRP-tetanus 
vaccine when administered simultaneously with a candidate 
DTPa-HBV-vaccine in the first 18 months of life. Successful in- 
duction of immunological memory occurred even when there was 
no measurable humoral anti-PRP response to the primary course. 
lmmunogenicity of the Acellular Pertussis 
Vaccine Combined with Diphtheria and 
Tetanus Toxoids (DTacP) and Haemophilus 
influenme Type B and Tetanus Toxoid (PRP-T) 
Conjugated Vaccine in Mexican Children at 18 
Months of Age 
H.L. Alvarez 
M. Esteva 
'Hospital de Infeaologia, Centro Mldico "La Raza" (LMSS), Mexico, 
'Pasteur Mkieux Connaught, Canada 
Objective: To compare the immunogenicity of the five-component 
DTacP vaccine and PRP-T vaccine, adrmnistered combined (A) or 
separate (B) vs. the immunogenicity of the whole cell pertusis MC- 
cine (DPT) and PRP-T administered combined (C). 
Methods: Double bhded, randomized, controlled study, in 102 
children who had received primary immunization with DPT. Im- 
munogenicity was assessed by measurements of antibodies to all vac- 
cine antigens. 
I? Del Villar A. Martinez ' , G.Y. Bacz I ,  
W. Schaart ', C. Miiller ', S. Mitter ', L. Barreto '. 
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Results: Immune response to all antigens in A, B and C groups 
was excellent. Th~s response (GMT) for Diphtheria and Tetanus, 
PRP and Pertussis agglutinins was comparable in all three groups. 
PT, FHA, FIM and Pertactin responses were higher in A and B 
than in C (p 5 0.02 for PT and Pertactin). Both DTacP groups (A 
and B) had comparable responses. Protective titres (20.1 IU/ml) for 
Diphtheria and Tetanus were present in 73-92% of children pre and 
in 100% post-immunization. Protective titres for PRP (20.15 ug/dl) 
in 81% of chlldren pre and in 100% post-immunization. 
Conclusion: The immune response, in children who received 
the five-component DTacP and PRP-T combined or separate, was 
comparable. Pertussis antibody responses were higher in children 
receiving DTacP than those who received DPT. Immunogenicity to 
PRP-T did not change when it was reconstituted with DTacP or 
DPT. This study indicates that Mexican children primed with three 
doses of DPT could receive a booster with the five-component 
DTacP to reconstitute PRP-T. 
RCT of ibuprofen vs. Acetaminophen for 
Preventing Fever from 
Whole-Cell-Pertussis-Containing DTP 
Vaccination 
J.S. Cavaness, R.M. Jacobson, G.A. Poland, P.C. Wollan. M q o  
Clinic, Rochester, Minnesota, U S A  
Objective: To determine the effkacy of ibuprofen versus ac- 
etaminophen in fever prevention in the 48 hours after whole-cell 
pertussis-containing DTP vaccination. 
Methods: In this double-blind trial, we randomized healthy sub- 
jects aged 6-18 months due for routine DTP-Hib or DTP vaccina- 
tions to receive post-vaccination either ibuprofen (9.5 mg/kg) at 0 
and 8 hours (placebo at 4 hours) or acetaminophen (15 mg/kg) at 0, 
4, and 8 hours. The child's parent measured fever (rectal temperature 
> 38°C) and other adverse reactions during the next 48 hours. 
Results: Of the 306 enrolled, 52% were male, and 91% Cau- 
casian. 155 received ibuprofen, and 151 acetaminophen. The 2 
groups were comparable in distribution of gender, race, vaccina- 
tion status, dose of DTP-containing vaccine due, age, and weight. 
44% had fever with ibuprofen, whde only 33% had fever with ac- 
etaminophen (p = 0.051). Using maximum temperature (Tmax) 
measured over the following 48 hours, the mean Tmax was 38°C for 
ibuprofen and 37.7"F for acetaminophen (p c 0.01). The rate of any 
adverse reaction was s d a r  - ibuprofen, 88%. and acetaminophen, 
90%. The rate of moderate-severe reactions was 55% with ibuprofen 
but only 39% with acetaminophen (p < 0.01). 
Conclusions: Ibuprofen did no better than acetaminophen in 
preventing fever &om whole cell pertussis containing DTP vaccina- 
tion. The rates were the same and in fact the Tmax was lugher with 
ibuprofen. Furthermore, ibuprofen appears to result in higher rates 
of moderate-severe adverse reactions. 
p] Immunization of Adults Against Diphtheria in 
A. Zakrzewska ', D. Rymkiewicz 
Hygiene, Poland, 'Sera and Vaccines Central Research Laboratory, 
Warsaw, Poland 
Objectives: Immunological response of Td vaccine in adults. 
Methods: Three groups of adult volunteers received one dose 
of Td vaccine: 51 students, aged 19 to 24 years, 40 adult &om 
Warsaw (25-65), 44 adult horn Krakow (22-57). Tetanus-diphtheria 
vaccine with a reduced amount of diphtheria toxoid (2Lf per dose) 
has been produced locally since 1993. Blood samples were taken just 
Poland 
J. Walory'. 'National Institute of 
before and 4 weeks after immunization, and the level of diphtheria 
antibodies was determined by passive haemagglutination test. 0.1 
I U / d  was considered as a protective level. 
Results: Td vaccine was well tolerated, slight and temporary re- 
actions were reported 1-2 days after immunization and disappeared 
after 2-3 days. 66% of volunteers was protected against diphthe- 
ria before immunization. The group aged 19 to 24 years showed a 
higher level of immunity than the oldest. after vaccination the ge- 
ometric mean of diphtheria antibody titters increased sigmficantly 
in the people who had been previously vaccinated against diphthe- 
ria. Volunteers with moderate levels of protective antibodies were 
reimmunised with monovalent diphtheria toxoid "d". 
Conclusions: One booster dose of Td vaccine stimulated o good 
production of diphtheria antibody. 
I PI411 1 Vaccination with Pertussis Toxoid Decreases 
Spread of Pertussis within the Family 
B. Trollfors ' , J. Taranger 
University, Sweden, ' N I C H D ,  National Institutes of Health, U S A  
Background: General vaccination will not only protect the vacci- 
nees, but may also induce herd immunity. 
Methods: During a double-blind, placebo-controlled trial of an 
acellular pertussis toxoid vaccine (developed at NIH, USA; rnanu- 
factured by AMVAX, USA) the risk of pertussis was investigated in 
parents and younger sibhgs of 3450 vaccinees, randomized to re- 
ceive DT toxoids with or without pertussis toxoid at 3, 5 and 12 
months of age. During 2 years after the 3rd vaccination pertussis 
cases were actively diagnosed in all family members (N = 11,000). 
Results: Pertussis with paroxysmal cough >21 days (definition of 
WHO) was diagnosed in 11 DTP parents and in 26 DT parents; 
indirect protection 60 percent (95% CI: 1682%). In younger sib- 
h g s  there were 10 WHO cases in the DTP group and 18 cases in 
the DT gmup; indirect protection of 43% (-1-76%). When cases of 
pertussis with cough 3 7  days were included, indirect protection was 
44% (7-67%) in parents and 56% (941%) in younger siblings. 
Conclusion: Vaccination of children with pertussis toxoid de- 
creases the risk of pertussis in close contacts, basis for the induction 
of herd immunity. 
T. Lagergird ', J.B. Robbins '. ' Gteborg 
I PI412 I Kinetics of Humoral Immune Response to 
Hemagglutinin and Neuraminidase After 
Vaccination with SplH Influenza Vaccine 
G. Glowacka-Bartnicka, L.B. Brydak. National Institute $Hygiene, 
Warsaw, Poland 
Objectives: The aim of this study was to evaluate the kinetics of 
hemagglutination inhibition (HI) and neuraminidase mhibition (NI) 
antibodies after vaccination against influenza in the epidemic season 
1993/1994. 
Methods: One hundred and eighty-eight volunteers in four 
merent age groups (young people, adults, middle-aged people, 
the elderly) were immunized with trivalent split d u e n z a  vac- 
cine (Vaxigrip, Pasteur-Merieux) and compared with a control 
group of 108 volunteers of the same age. Antibodies were de- 
termined in pre-vaccination sera and three week and six month 
post-vaccination sera. The hemagglutination inhibition (HI) test and 
neuraminidase inhibition (NI) test were performed by a routine 
technique for viruses recommended by the WHO for the epidemic 
season 1993/1994. 
Results: Mean fold antibody increase was highest for the compo- 
nent H1 (17.9), medium for H3 (6.2) and lowest for the component 
HB (3.5). The mean fold antibody increase for neuraminidase was 
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highest for the component NB (13.8), lower for N2 (2.97) and low- 
est for the component N1 (2.6). 
Conclusions: Antibody responses measured by hemagglutination 
and neuraminidase inhibition titration showed Werent kinetic pat- 
terns. Geometric mean titres for hemagglutinin and neuraminidase 
were notably higher six months after vaccination than before vacci- 
nation. 
[p14131 Influenza Immunization: improving 
Compliance of Health Care Wokers (HCW) 
S. Harbarth, C.A. Siegrist, J.C. Schira, D. Pittet. Univenity Hospitak 
of Geneva (HUG) ,  Switzerland 
Objective: In spite of yearly recalls, influenza immunization rates of 
HCW remained low (< 10%) in HUG. Ths study was conducted to 
1) identify HCW reasons for rejection of immunization, 2) design 
specific intervention methods based on these reasons and 3) evaluate 
the impact of such interventions. 
Methods: 3 departments with high-risk patients (geriatrics, ob- 
stetrics and pediatrics) were selected as main targets and question- 
naires were distributed in these units. Based on HCWs’ perceptions, 
we employed 4 intervention methods to increase compliance: (1) 
educational conferences; (2) posters (“talking walls”); (3) personal 
letters; (4) on-site availabhty of a vaccination nurse. Immunization 
rates were collected throughout the institution. 
Results: 79711300 (61%) questionnaires were received and the 
main reasons for immunization rejection identified. During the 
8-week period after start of the promotion campagne, 1441 (26%) 
of 5432 HCW were vaccinated in HUG. In the 3 selected de- 
partments with high-risk patients, influenza immunization rates rose 
dramatically (fmm t10% to 37%). Nurses were more reluctant to 
immunization compared to other HCW 
Conclusions: Influenza immunization rates of HCW can be in- 
creased by specific interventions among which the on-site a d a b h t y  
of a vaccination nurse appeared essential. 
1 PI414 I Development of a Salmonellabased 
Prophylactic Vaccine Against Human 
Papillomavitus HPV 16 
D. Nardelli-Haefliger ’, R.B. Roden ’, J. Benyacoub I ,  R.  Sahli ’, 
J.2 Kraehenbuh14, J.T. ScMer’, A. Potts’, l? Lachat’, l? De 
Grandi I .  ’Department of Gynecology, 31nstitute $Microbiology, C H U Y  
Lausanne, Switzerland, 41nstifute of Biochemishy, U N I L ,  and ISREC, 
EpaZinges, Switzerland, ’Laboratory of Cellular Oncolon, N C I ,  
Bethesda, USA 
The induction of neutralizing antibodies in genital secretions may 
be critical for the effectiveness of a prophylactic vaccine against gen- 
ital human papillomaviruses (HPV), which are associated with the 
development of cervical cancer. Attenuated strains of Salmonella are 
attractive live vaccine candidates for eliciting mucosal as well as sys- 
temic immune responses. The L1 major capsid protein of HPV16 
has been expressed in the PhoPc strain of S. typhimurium in which it 
self-assemble into virus-like particles (VLPs) that resemble authentic 
HPV virions. BALB/c mice were immueed with the HPV16 L1 
recombinant PhoPc strain by the oral and nasal route. Despite a low 
stability of the L1-expressing plasmid in viuo, a double nasal immu- 
nization was effetive in inducing L1-specific antibodies in serum. 
These antibodies recognized native VLPs and effectively n e u h e d  
HPV16 pseudotyped virions in an in uitro infectivity assay. Anti-VLP 
IgA and IgG were also detected in oral and vaginal secretions, in- 
dicating that potentially protective antibodies were elicited at these 
sites. Recombinant Salmonella expressing HPV capsids are a promis- 
ing vaccine candidate against genital HPV lnfection and we are cur- 
rently testing new strains that maintain the plasmids and could be 
used in human. 
Creation of Salmonella enteritidis Mutant with 
Stable Avituient Phenotype 
M. Boitchenko, S. Ryjova. Department ofMicrobiology Sechenou 
Medical Academy, Moskow, Russia 
Objectives: Though salmonellosis remains one of the actual prob- 
l em in memcine and veterinology the creation of attenuated 
Salmonella strains is actually. Attenuated Salmonella strains are also 
suitable as delivery-strains of heterologous antigens. As species 
Salmonella enteritidis is the main causative agent of salmonellosis in 
Russia, creation of attenuated mutant of this species will be perspec- 
tive, as such mutant could be used as vaccine strain in veterinology 
or delivery-strain. 
Methods: Mutant was obtained fmm the strain of the wild type 
S. enteritidis 1791 during processes of transduction and next di- 
rect selection. Created mutant, named S. entm’tidis E-23 was de- 
terminated as cya* (cya-suppressor) mutant, because E-23 possesses 
cya (lacing adenilatecydase) mutation with CRP-phenotype (lacing 
c-AMP-receptor protein). Mutant E-23 didn’t possess any antibiotic 
resistance. 
Results: 1 g LD 50 of E-23 -8.5; 1 g LD 50 of parent st ra in  -1 
after intraperitoneally inoculation of mice. Mutant E-23 possessed 
of stable avirulent phenotype: 1 g LD 50-9 after 8 passing through 
mice organism. Mutant E-23 has persisted in mice during 45 days 
after single oral application. No secretion of the mutant and no 
any change in mice enteric microflora during period of persistence 
was observed. Mutant E-23 didn’t W e r  stable phenotype and other 
properties after deep cultivation and preparation of dry vaccine form. 
Conclusion: Cya s mutant of S. entm’tidis with stable avirulent 
phenotype and capability to persist in mice after single oral applica- 
tion was obtained. 
Ip141s] PCR System for identification of lcrp Mutation 
in Salmonella 
S. Tymchuk’, N. Selivanov’, M. Boitchenko’, A. Vorobiev’. 
’Ivanousky Institute of Virology, Moskow, Russia, ’Department of 
Microbiology Sechenov Medical Academy, Moskoq  Russia 
Objectives: Elaboration of the new generation of recombinants vac- 
cines for oral application is one of the perspective scientific trend in 
modern microbiology. Attenuated Salmonella strains have received 
the most attention as perspective carries of heterologous antigens. 
Cya and crp mutants (lacing adenylatecyclase and c-AMP receptor 
protein, respectivity) of Salmonella have been received the achowl- 
edgment among a attenuated Salmonella. The methods of genetic’s 
recombination by transduction and transformation are preferable for 
creation such mutants. For this purpose we decided to create donor’s 
strain, possessing genetic’s marking Acrp mutation and laboratory 
investigating system for identification such mutation. 
Methods Donor’s strain S. typhimurium B-5 have been obtained 
by treatment with phage P22 (TnlO) and next exdusion of TnlO. 
The Acrp mutation was estimated by determination of nucleotide 
sequence. PCR method was used for determination of Acrp muta- 
tion. 
Resul- Mutant S. typhimurium B-5  possessed deletion with 7 
nucleotides in crp gene. Acrp gene has been transducted to other 
wild type strains of Merent species of Salmonella. For determination 
Acrp mutation the special primer’s, complementary Acrp gene were 
elaborated. 
Herpes viruses (HSV, VZV, EBV and HHV-6) 351 
Conclusion: Salmonella mutant with deletion of 7 nucleotides in 
crp gene was obtained. The special PCR-system for determination 
such mutation was created. 
I P1417 I Antibody Response to Campylobacter 
Antigens in Immunized Mice 
M. Mikhail, Z.S. Mohran, M.O. Wasfj~, B.A. Oyofo, T.E Ismail, 
L.E Peruslu. US Naval Medical Researrh Unit No. 3, Cairo, Egypt 
Objective: Evaluation of Campylobactmjejuni and coli antigenic com- 
ponents which elicit an immune response and identification of classes 
of antibodies stimulated. 
Methods: Five C. jejuni and four coli strains representing a range 
of Lior serogroups and flagellar gene polymorphism groups were 
used to intranasally challenge nine groups of Balb/c mice. Antigenic 
components of each strain were determined by SDS-PAGE and im- 
munoblotting ofbacterial cell onicates (CS) and acid-glycine extracts 
(AGE) with immune mouse serum. 
Results: Protein profiles of CS and AGE showed heterogeneity of 
flagellar proteins (molecular mass (M,) range 58k to 61k) and Mer- 
ences in M, of these and other cellular components. Immunoblotting 
of CS and AGE with homologous and heterologous mouse serum 
demonstrated IgG, IgA and IgM reactions to at least one flagellar 
protein, but only IgA and IgG reactions to outer membrane proteins 
(OMP, M, 20k and 25k) and other cellular components (M, 40k and 
45k) of CS. Immunoblotting of CS with IgG subclasses showed that 
flagellar components were recognized by IgGl , IgG2 and IgG3 anti- 
bodies whereas OMP and other components were only recognized 
by IgGi and IgGz. 
Conclusions: Strain differences observed in protein profiles, in- 
munogenicity and relative antigenicity of protein components were 
not related to Lior serogroup or polymorphc group differences. In 
all strains examined, flagellar proteins showed higher cross-reactivity 
and stimulated all classes and subclasses of antibodies, suggesting their 
involvement in all aspects of host defense, induction of cytotoxicity 
and in protective immunity. 
I P1418 I Analysis of Corynebacterium diphtheriae Toxin 
IgG Antibody in Sera of Healthy Population in 
Poland 
J. Wdory I ,  A. Zakrzewska ', W Gut ', S. Tyski ' . 'Sera and Vacn'nes 
Central Research Laboratory, Warsaw, Poland, 'National Institute .f 
Hygiene, Warsaw, Poland 
Diphtheria is an endemic dlsease in many regions of the world due 
mainly to inadequate health-care delivery systems. The recent out- 
breaks of diphtheria in Belarus, the Russian Federation and Ukraine 
poses a threat to neighbouring countries, including Poland. An in- 
creased incidence of diphtheriae has already been reported in hs 
country. The aim of this study was to standardise an ELISA for the 
determination of speclfic I& against C. diphtheriae toxin, in order to 
measure the protective antibody level in the sera of healthy people. 
The normal level of antibodies against diphtheria toxin in over 400 
serum samples &om healthy population in different age groups (10 
samples each in intervals of one month over the first year of Me and 
then 10 samples each in consecutive years) and adequate diphtheria 
immunisation status was determined. The optimum antigen coating 
dose - 2.5 Lf of diphtheria anatoxin per ml of carbonate buffer pH 
9.6 was estimated. The optimum dilutions for specific IgG determi- 
nation for serum samples and the peroxidase conjugate were defined 
to be 1: lOO and 1:5000 respectively. Antigenantibody incubation 
and conjugate treatment were performed for 1 hour at 37°C. The 
British NBSB diphtheria antitoxin human serum was used as a refer- 
ence. The obtained results of analysed sera were calculated according 
to standard cume. Consecutive vaccination increases anti-diphtheria 
IgG level, what was demonstrated by geometric mean titer calcula- 
tion. The protective antibody level (0.1 JA/ml) in analysed samples 
was calculated for each particular age group. The lack of significant 
protective antibody level was observed in some sera samples of the 
adult group. 
1 P1419 1 The Effect of Immunization with 
"Pervalur"-Tortak (polyvalent urovaccine) 
M. Vignjevit-Krastavtevit 
and Immunology and Virology Erlak, Belgrade, Yugoslavia, 'Institute for 
Renal Diseates, Zvesdara University Hospital, Belgrade, Yugoslavia 
Objectives: "Prevalur"-Torlak is polyvalent vaccine with inactivated 
uropathogenic bacteria. It consists of 7 bacterial strains in appropriate 
concetration. Immunological response and protective efficacy of this 
vaccine have been examinated. 
Methods: Active immunization have been applied in 63 persons, 
mostly female, age 21 to 71 with recurrent urinary tract infection. 
Vaccine was given subcutaneously 3 doses at weekly intervals and 4th 
one month after the 3rd. The titres of specific circulatory antibodies 
were followed on days O., 21. and 45. by agglutination test and total 
amount of IgG, IgA and IgM in serum were determined by RID 
method. All patients were examined during twelve months. 
Results: "Prevalur"-Torlak induces formation of specific antibod- 
ies and the antibody titres increased 4-fold and more in all patients 
after 21th day (mean 1:2.88.39) and 45th day (1:681.39) compared 
to 0th day (1:44.17). This immunization led to significantly higher 
serum IgG and IgA (p < 0.001) in 48 persons. In 26 patients f?e- 
quency of recurrent UTI was reduced from 1 episodall.5 patient 
months to 1 episoda/6.3 patientrnonths, and 38.09% ofpatients were 
without infection during the period of examination. 
Conclusions: Immunization with "Prevalur"-Torlak induces the 
formation of specific antibodies in s i m c a n t  titres in all patients 
and increases of total amount of serum IgG and IgA in 76.19%. 
The protective effect in majority of patients leads to conclusion that 
polyvalent vaccine might be applied safely to the patients su6ering 
&-om UTI. 
G. Da!& I ,  N. Dimkovit *. ' Institute 
Herpes viruses (HSV, VZV, EBV and HHV-6) 
F 1  Susceptibility of Herpes Simplex Virus (HSV) 
to Acyclovir: Absence of Correlation between 
Results Obtained in Vero and MRC-5 Cell Lines 
M. Cotarelo, P. Catalin, C. Shchez-Carrillo. A. Menasalvas, 
M. Rivera, E. Bouza. Hospital General Universitario "Gregorio 
Maraan", Madrid, Spain 
Objectives: To compare the susceptibility of clinical isolates of HSV 
to acyclovir (ACV) on Vero and MRC-5 cells and to evaluate its 
clinical correlation. 
Methods: Susceptibility testing was performed by the "standard" 
method of plaque reduction assay following the American Society 
for Microbiology guidelines on Vero cells as well as on MRC-5 cells. 
We considered a strain resistant when the ICso for ACV was greater 
than 2 fig/&. Three control s t r a i n s  were used, one susceptible to 
ACG: one resistant to ACV and one resistant to ACV and foscarnet. 
Results: Among the 33 isolates of HSV, 21 were susceptible to 
ACV on both cell lines. Twelve isolates were resistant to ACV on 
Vero cells, among them, five were resistant and seven susceptible 
